ABOUT US

Mabqi uses its proprietary phage display technology to deliver to our partners antibodies with the desired characteristics, fit for continued drug development.

Each asset is assigned to a dedicated team, focused on a single target at a time, to configure project plans and antibody selection schemes adjusted to the antigen and objectives.

Mabqi works in tandem with its corresponding academic platform “GenAc” and Inserm lab for very active research and R&D collaboration to continuously improve and innovate in our methods and tools.

Management team

Our team consolidates management excellence and best in class scientific expertise that can be traced back to the founding of fully human antibody phage display libraries.

Bernard Pau PhD

President & CS Advisor

Hon. Professor, Immunology, U-Montpellier. Former Head of the Department of Life Sciences CNRS, Paris. Director, entrepreneur, expert in the development of Biotech & Pharma innovation.

Sylvain Yon PhD

CEO

20 years of experience in medical devices and biotechnology startups. Sylvain is an active business angel and strategic consultant for some very promising ventures in healthcare. He holds an engineering degree from ESPCI ParisTech and a PhD from Paris Diderot University.

Gautier Robin PhD

CTO

PhD at University Joseph Fourier, Grenoble (Prof. R. H. Wade) 20 years of experience in academic and biotech research and management. Expert in protein engineering and phage display.

Maxime Waldron

CFO

Investment banking background (M&A and ECM) and Finance Lecturer at Sorbonne University

Anne Chevrel PhD. M. Eng

Head of Discovery

More than 10 years of experience in protein engineering and discovery

Johanna Marines PharmD. PhD. M. Eng

Head of Preclinical

Tumor microenvironment expert

Cécile Durand

Business Development Director

20 years' experience in international business development for innovation-driven CROs and start-ups in the biopharmaceutical industry. She holds a MS in Biochemistry.

Medical Advisory Board

Created in 2021, Mabqi Medical Advisory Board is composed of 4 International experts who provide medical and economic insight to identify and validate promising therapeutic targets with high clinical need.

Dr Diego Tosi, MD PhD

Medical Oncologist, Head of the Montpellier Cancer Institute (ICM) Early Clinical Phases Unit

Pr Guillaume Cartron, MD PhD

Head of the Hematology Department of Montpellier University Hospital

Pr Hervé Watier, MD PhD

Director of MabImprove Labex Immunology U-Tours

Dr Thierry Chardès, PharmD PhD

Pharmacist and Doctor of Sciences. Research director at CNRS, Montpellier

Key Advisors

Gordon Waldron

Advisor, Finance & BD

25 years experience working as CFO for start-ups primarily in the biotech sector. Raised > €150 million from international investor base and €50 million via IPO. Negotiated the sale of Novexel for $500 million.

Pierre Martineau PhD

Advisor & SAB Member

Engineer Polytechnique school. PhD at Biotechnology Department, Institut Pasteur, Paris (Prof. M. Hofnung). PostDoc at Cambridge (UK) Center for Protein Engineering (Sir G. Winter). Team leader Inserm (IRCM, Montpellier). Deputy Director, IRCM.

Bruno Robert PhD